Table 1 Characteristics of the 28 clinical trials
Study | Year | Study design | Sample size | Population | Intervention (mg/d) | Mean follow-up | End-points | NOS score |
|---|---|---|---|---|---|---|---|---|
Lofti et al. [20] | 2008 | RCT | 4162 | ACS | G1: A80 + Clo G2: P40 + Clo | 2 years | Death, MI, UA, stroke | – |
Malmstrom et al. [21] | 2009 | RCT | 69 | CAD PCI | G1: R10–40 + Clo G2: A20–80 + Clo G3: S40 + Clo | 16 weeks | PA, P-selectin, fibrinogen binding | – |
Mitsios et al. [22] | 2004 | RCT | 45 | ACS | G1: A10 + Clo G2: P40 + Clo | 5 weeks | PA, P-selectin, CD40L, lipids, ALT, AST, LDH, CK | – |
Neubauer et al. [10] | 2003 | Prospective cohort | 47 | CAD | G1: S10/S20/A20/A40 + Clo G2: Clo | 48 h | P-selectin | 9 |
Ojeifo et al. [23] | 2013 | Cohort | 4794 | ACS | G1: Statin + Clo G2: Clo | 450 days | Cardiovascular death, MI, stroke | 7 |
Park et al. [24] | 2016 | RCT | 3755 | PCI | G1: CYP3A4 + Clo G2: non-CYP3A4 + Clo | 1 month | PRU, death, MI, revascularization, stent thrombosis | – |
Poyet et al. [25] | 2010 | RCT | 138 | ACS PCI | G1: A80 + Clo G2: R20 + Clo | 1 month | PA, LDL-C, HDL-C, CRP | – |
Schmidt et al. [26] | 2012 | Cohort | 13,001 | PCI | G1: Statin + Clo G2: Clo | 12 months | MACE | 7 |
Serebruany et al. [6] | 2005 | Prospective cohort | 75 | PCI | G1: A10–40 + Clo G2: other statins + Clo G3: Clo | 24 h | PA, P-selectin, CD40L, CD63, PAC-1 | 8 |
Suh et al. [27] | 2014 | Prospective cohort | 556 | PCI | G1:A20 + Clo G2:R10 + Clo | 6 months | PRU, lipids, MACE, death, MI, stent thrombosis, ischemic strike, target lesion revascularization | 7 |
Toso et al. [28] | 2017 | Cohort | 1053 | ACS PCI | G1: Statin + Clo G2: Clo | 1 year | PRI, MACE, death, Cardiac death, MI, stent thrombosis, stroke | 7 |
Vinholt et al. [29] | 2005 | Cohort | 66 | CAD | G1: CYP3A4 + Clo G2: non-CYP3A4 + Clo | 21 days | PA, TC, LDL-C | 9 |
Wenaweser et al. [30] | 2010 | RCT | 101 | CAD PCI | G1: A40 + Clo G2: F80 + Clo | 1 month | PA | – |
Wenaweser et al. [31] | 2007 | RCT | 73 | PCI | G1: A20/P40 + Clo G2:Clo | 1 month | PA, lipids, CRP | – |
Zhang et al. [32] | 2015 | RCT | 104 | NSTE-ACS PCI | G1: A20 + Clo G2: Clo | 6 months | IPA, P-selectin, TBX2, sCD40L | – |
Gorchakova et al. [19] | 2004 | Cohort | 180 | CAD PCI | G1: A/S + Clo G2: Clo | At least 4 weeks | Maximal PA, Residual PA, P-selectin, CD61 | 8 |
Lim et al. [15] | 2005 | Prospective cohort | 15,693 | ACS | G1: statin + Clo G2: Clo | 6 months | Rehospitalization, stroke, revascularization, death | 9 |
Nagavi et al. [33] | 2016 | Prospective cohort | 61 | PCI | G1: A40 + Clo G2: R40 + Clo G3: Clo | 24 h | PA | 7 |
Riondino et al. [34] | 2009 | Cohort | 105 | PCI | G1: A20 + Clo G2: R10 + Clo G3: Clo | 3 months | PA | 8 |
Trenk et al. [11] | 2008 | Cohort | 1395 | PCI | G1: A + Clo G2: S + Clo G3: F + Clo G4: P + Clo G5: Clo | 1 year | RPA, P-selectin, CD63, PAC-1, MACE, death, MI, target lesion reintervention | 7 |
Mitsios et al. [35] | 2005 | Cohort | 51 | ACS PCI | G1: A + Clo G2: Clo | 5 weeks | PA, P-selectin, CD40L | 7 |
Mukherjee et al. [36] | 2005 | Prospective cohort | 1651 | ACS | G1: CYP3A4 + Clo G2: non-CYP3A4 + Clo G3: Clo | 6 months | death, MI, stroke, MACE | 8 |
Lau et al. [4] | 2003 | Prospective cohort | 44 | PCI | G1: A + Clo G2: P + Clo G3: Clo | 24 h | PA | 8 |
Matetzky et al. [37] | 2010 | Cohort | 120 | STEMI | G1: statin + Clo G2: Clo | 72 h | PA | 9 |
Brophy et al. [16] | 2006 | Retrospective cohort | 2927 | PCI | G1: A + Clo G2: Clo | 30 days | death, MI, UA, repeat revascularizations, stroke, transient ischemic attack | 7 |
Pelliccia et al. [38] | 2014 | RCT | 122 | CAD | G1: A40 + Clo G2: R20 + Clo | 30 days | PRU, lipids | – |
J.-M.Lablanche et al. [39] | 2010 | RCT | 753 | ACS | G1: A80 + Clo G2: R20 + Clo | 3 months | lipids, MI, stroke, death, UA, repeat revascularization | – |
Guo et al. [40] | 2017 | RCT | 137 | ACS PCI | G1: R10 + Clo G2: Clo | 1 year | Restenosis, death, MI, target vessel revacularization | – |